ABSTRACT
Background Healthcare workers are at increased risk of exposure to respiratory pathogens including Streptococcus pneumoniae (pneumococcus). While little asymptomatic carriage has been reported in young-to-middle-aged adults, this may be due to non-sensitive diagnostic methods. The aim of the study was to investigate the rates of pneumococcal carriage in a large cohort of healthcare workers using saliva as a respiratory specimen.
Methods We evaluated the prevalence of pneumococcal carriage in a convenience sample of saliva, self-collected from asymptomatic healthcare workers at Yale New Haven Hospital (CT, USA) who were testing for SARS-CoV-2 from March 30 to June 11, 2020. Samples were transported at ambient temperature and stored at −80°C within 12 hours. DNA extracted from the culture-enriched saliva was later tested using qPCR for piaB, lytA, and serotype. Saliva samples were considered positive for pneumococcus when the piaB Ct value was <40.
Results Study participants were 22-74 years old (mean=38.5), 75% female, 75% white, with occupations including registered nurses (48%), medical doctors (23%), and patient care assistants (5%). Overall, 138/1241 (11%) samples from 86/392 (21%) individuals tested piaB-positive for pneumococcus at some point during the 4-month study period, with 28 (33%) colonized individuals positive at multiple time points. Carriers reflected the overall study population. No significant demographic characteristics were associated with detection of pneumococcus. Colonized individuals primarily carried serotypes 19F (25%) and 3 (12%), however, we were unable to resolve a primary serotype for 31% of all pneumococcus-positive samples identified.
Conclusions During a period of mandatory masking, we identified a cumulative pneumococcal carriage prevalence of 21% among healthcare workers. This study highlights that healthcare workers may act as unrecognized reservoirs of pneumococcus in the population. Despite long-standing PCV7 and PCV13 pediatric immunization programs, vaccine serotypes continue to be prevalent among the adult population.
Competing Interest Statement
ALW has received consulting and/or advisory board fees from Pfizer, Merck, Diasorin, PPS Health, Co-Diagnostics, and Global Diagnostic Systems for work unrelated to this project, and is the Principal Investigator on research grants from Pfizer, Merck, NIH RADx UP, and SalivaDirect, Inc. to Yale University and from NIH RADx, Balvi.io, and Shield T3 to SalivaDirect, Inc.. DMW has received consulting fees from Pfizer, Merck, GSK, Affinivax, and Matrivax for work unrelated to this project and is the Principal Investigator on research grants and contracts with Pfizer and Merck to Yale University. RD1 was a former employee of Janssen Research and Development. All other co-authors declare no potential conflict of interest.
Funding Statement
This study was conducted as a collaboration between Yale School of Public Health and Pfizer. Yale School of Public Health is the study sponsor. The study protocol was designed by the Yale researchers in consultation with Pfizer. The decision to publish was made by the Yale researchers in consultation with Pfizer; all authors agree with the decision to publish and with the results of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical staff at Yale New Haven Hospital were eligible to participate in the study voluntarily. All study participants were enrolled and sampled in accordance with the Yale University Human Investigation Committee-approved protocol #2000027690. Demographics, clinical data, and samples were collected after the study participant acknowledged that they understood the study protocol and provided informed consent. All participant information and samples were collected in association with non-individually identifiable study identifiers.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
